A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
NCT06535412
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
218
Enrollment
OTHER
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
DRUG:
IMC-002 + SOC
DRUG:
Placebo + SOC
Sponsor
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.